Table 6. Aggregate meta-analysis of the cumulative incidence of drug-resistant TB by aggregated TPT regimens.
| Group | Number of studies | n/N | Pooled cumulative incidence of drug-resistant active TB per 100 people randomized (95% CI) | I2 |
|---|---|---|---|---|
| Proportion of any resistance | ||||
| 6 to 12 H | 11 | 27/6,441 | 0.42 (0.28 to 0.64) | 12% |
| 24 to 72 H | 3 | 4/1,444 | 0.28 (0.1 to 0.74) | 0% |
| Any mono-H | 14 | 31/7,885 | 0.39 (0.27 to 0.57) | 7% |
| Rifamycin containing | 7 | 9/3,092 | 0.31 (0.12 to 0.77) | 42% |
| Placebo or no treatment | 7 | 16/2,796 | 0.22 (0.03 to 1.81) | 87% |
| Proportion of resistance to H (including MDR) | ||||
| 6 to 12 H | 11 | 24/6,441 | 0.39 (0.23 to 0.66) | 39% |
| 24 to 72 H | 3 | 4/1,444 | 0.28 (0.1 to 0.74) | 0% |
| Any mono-H | 14 | 28/7,885 | 0.37 (0.24 to 0.57) | 23% |
| Rifamycin containing | 7 | 6/3,092 | 0.18 (0.05 to 0.69) | 55% |
| Placebo or no treatment | 7 | 12/2,796 | 0.2 (0.03 to 1.53) | 84% |
| Proportion of resistance to Rif (including MDR) | ||||
| 6 to 12 H | 11 | 6/6,441 | 0.09 (0.04 to 0.21) | 0% |
| 24 to 72 H | 3 | 3/1,444 | 0.21 (0.07 to 0.64) | 0% |
| Any mono-H | 14 | 9/7,885 | 0.11 (0.06 to 0.22) | 0% |
| Rifamycin containing | 7 | 7/3,092 | 0.24 (0.07 to 0.81) | 55% |
| Placebo or no treatment | 7 | 6/2,796 | 0.21 (0.1 to 0.48) | 0% |
Any mono-H includes 6 to 72 H; rifamycin-containing regimens include 3HR, 3HP, and 1HP; overall resistance includes all types of drug resistance reported in individual studies; not all studies carried out drug susceptibility testing for all first line anti-TB drugs. Results should be interpreted as follows: Among studies evaluating 6 to 12 H, there were 0.42 cases of drug-resistant TB per 100 people randomized.
CI, confidence interval; MDR, multidrug resistant, resistant to H and R; TB, tuberculosis; TPT, tuberculosis preventive therapy.